Particularly for papillary thyroid cancer, we identified the prevalence of BRAF V600E mutations in 68.4% of the samples, which was at the high end of the reported range (32%–65%) (Xing et al., 2013). This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.